Journal of Advances in Developmental Research (IJAIDR)

E-ISSN: 0976-4844 ● Website: www.ijaidr.com ● Email: editor@ijaidr.com

Artificial Intelligence in Pharmaceutical Formulation: A Review on Predictive Approaches for Excipient and Dosage Form Optimization

Shouvik Mondal[1], Hemant Kumar Pandey[2]

[1]Assistant Professor, Department of Pharmaceutics, Netaji Subhas University, Jamshedpur, 831012
[2]Research Scholar, Department of Pharmaceutics, Netaji Subhas University, Jamshedpur, 831012

Abstract:
The design of pharmaceutical formulations plays a crucial role in ensuring the effectiveness, safety, and long-term stability of therapeutic products. Traditionally, the formulation process has relied on empirical methodologies, often involving laborious trial-and-error to identify suitable excipients and develop optimal dosage forms. These conventional strategies can be inefficient, costly, and frequently fall short in providing accurate predictions. This review explores the increasing integration of advanced AI technologies within formulation science, focusing particularly on their roles in the rational selection of excipients and refinement of dosage forms. Utilising large volumes of experimental data, AI-driven models have proven effective in forecasting excipient interactions, optimising formulation parameters, and anticipating essential quality indicators such as stability and performance. Approaches including neural networks, decision-based models, ensemble learning methods, and kernel-based classifiers have shown significant promise in streamlining formulation development and reducing manual workload. Furthermore, the use of AI is paving the way for individualised drug delivery systems tailored to patient-specific profiles, promoting advancements in personalised treatment. Numerous studies demonstrate how AI-enabled formulation strategies enhance not only efficiency but also therapeutic effectiveness. However, several hurdles remain, including limitations in data accessibility, variability in data integrity, challenges in model explainability, and the need for regulatory clarity. Collaborative engagement across research institutions, industry stakeholders, and policymakers will be critical in addressing these issues and promoting the practical implementation of AI.

Keywords: Artificial Intelligence, Formulation Science, Excipient Modelling, Dosage Form Design, Predictive Algorithms.

1. INTRODUCTION

Designing patient-friendly and therapeutically effective drug products remains a cornerstone of contemporary pharmaceutical innovation. Historically, formulation development has been rooted in practical experimentation, guided by accumulated knowledge and iterative testing. Although this approach has led to important medical advances, it often lacks efficiency, consumes extensive time and

resources, and provides limited foresight-especially when addressing complex drug systems or emerging delivery platforms [1,2].

In recent years, the integration of intelligent computational systems into pharmaceutical research has emerged as a game changer. Artificial intelligence (AI)-a broad field encompassing systems that emulate human thought processes-includes techniques such as data-driven learning algorithms, deep neural architectures, and pattern recognition models. These tools are capable of detecting hidden patterns and interrelationships within large datasets, thereby improving the speed and accuracy of formulation-related decision-making [3,4].

A particularly promising area is the application of AI to forecast and refine excipient compatibility and formulation design. Though excipients lack direct therapeutic action, they are essential for stabilising active ingredients, facilitating absorption, improving manufacturability, and enhancing patient adherence. The complexity of selecting appropriate excipient blends can be significantly reduced using algorithm-based prediction systems [5]. Likewise, the choice of formulation type-whether a capsule, suspension, immediate- or sustained-release system-has a direct influence on treatment outcomes and user experience [6].

Current studies indicate that AI-enabled platforms can anticipate critical quality parameters, optimise formulation design elements, and simulate responses both in lab settings and within physiological environments, all while reducing reliance on exhaustive experimentation [7,8].

These innovations accelerate the formulation cycle and contribute to more streamlined drug development. Additionally, AI supports implementation of modern regulatory practices like Quality by Design (QbD) by identifying material attributes and essential operational variables that uphold consistency and compliance across production batches [9]. Nevertheless, certain barriers remain - such as the need for high-quality datasets, interpretability of complex models, alignment with regulatory expectations, and user-friendly interfaces for non-technical professionals [10]. This review aims to deliver a detailed exploration of how AI is transforming formulation science, with a focus on predictive modelling for excipient selection and dosage optimisation, while also discussing emerging directions in this evolving field.



Figure 1: Overview of AI Integration in Pharmaceutical Formulation Workflow

2. AI-DRIVEN INNOVATIONS IN DRUG DEVELOPMENT

Harnessing artificial intelligence within pharmaceutical formulation has opened new avenues for designing drug therapies in a more predictive and structured way. Among the most impactful applications are intelligent excipient pairing, formulation strategy refinement, and integration with regulatory paradigms like the Quality by Design (QbD) framework.

2.1. Smart Excipient Selection

Identifying the right excipients is crucial to ensuring a drug product's performance in chemical stability, therapeutic absorption, and ease of manufacturing. Conventionally, this process relied on trial-and-error methods and labour-intensive experiments. With the emergence of AI - particularly algorithms rooted in data-driven modelling - formulators can now evaluate physicochemical traits and past formulation outcomes to identify compatible excipients and streamline development [1,11,12] efficiently.

Techniques under supervised learning - such as decision tree algorithms, SVMs (support vector methods), and ensemble classifiers like random forests - are being used to predict how excipients and active compounds might interact. These models evaluate essential formulation factors, including water affinity, dissolution behaviour, and molecular integrity, to enhance overall product design [2,12]. Meanwhile, unsupervised methods like similarity-based clustering assist in categorising excipients by shared properties, accelerating initial screening phases [11].

2.2. Formulation Strategy Enhancement

Artificial intelligence plays a pivotal role in refining pharmaceutical dosage strategies by uncovering how variables like release kinetics, mechanical strength, disintegration behaviour, and systemic absorption interact. Through advanced simulations, AI-driven systems assist in pinpointing the most effective formulation approach for a wide array of delivery systems, including solid orals like tablets and capsules, as well as emulsions, suspensions, and transdermal applications [4,5,14].

Computational approaches such as neural models and evolutionary algorithms have shown strong potential in forecasting ideal processing conditions - like blending durations, granulation settings, and compression intensity. These tools are especially valuable in the development of modified-release formulations, where the synergy between excipients and polymers demands precise control [6,14].

2.3. Incorporating AI within Quality by Design Frameworks

Artificial intelligence aligns well with the foundational principles of Quality by Design (QbD), which focus on thorough process comprehension, defining operational flexibility, and proactive risk mitigation. AI contributes significantly by uncovering key quality determinants and essential process variables, while also enabling the exploration of complex formulation scenarios through advanced simulations and intelligent data analysis [7,9,13].

Embedding AI technologies into QbD processes has demonstrated improvements in reducing variability and strengthening adherence to regulatory standards. Moreover, AI-supported systems facilitate ongoing process oversight and enable predictive quality assessment, ensuring consistency with evolving industry compliance requirements. [8,13,14].

Table 1: Applications of AI in Pharmaceutical Formulation [1,3,7,13,14]

Application Area	AI Contribution	Common Tools
Excipient Selection	Predicting compatibility and optimal ratios	SVM, Decision Trees, Random Forest

Dosage Form Optimisation	Modelling release profiles, hardness, stability	Neural Networks, Genetic Algorithms
Quality by Design (QbD)	Identifying CQAs, CPPs, design space simulation	Data Mining, PCA, ANN
Manufacturing	Real-time monitoring, predictive maintenance	IoT-integrated AI, Bayesian Models
Literature Mining	Extracting formulation data from patents and publications	NLP, Transformers

Figure 2: Visual Representation of AI Applications in Formulation



2.4. Computational Approaches and Strategies in Formulation Development

Applying intelligent systems to pharmaceutical product design involves various computational approaches and digital solutions. The use of machine intelligence in this context is supported by a wide spectrum of platforms and algorithms. Each framework varies in its design logic, method of learning, and area of application - offering distinct benefits depending on the specific phase of formulation work.

2.5. Predictive Modelling Approaches in Formulation Development

In pharmaceutical formulation, intelligent data-driven approaches are increasingly leveraged to forecast outcomes and optimise processes. Algorithms under the umbrella of computational learning, particularly those in the supervised category - such as support vector classifiers, random forest ensembles, and k-nearest neighbour methods - excel in associating formulation parameters like excipient composition with critical properties such as dissolution profiles and tablet mechanical strength [15,16]. These methods depend on well-annotated datasets, making them ideal when historical experimental results are available. In contrast, pattern discovery methods that operate without labelled outputs - like principal component analysis (PCA) and clustering - are valuable for identifying underlying structures and classifying similar

formulations or ingredient groups. Such tools are especially useful during early-stage formulation exploration and hypothesis generation [17].

Figure 3: Roles of Machine Learning in Drug Development



2.6. DL (Deep Learning)

Deep learning, an advanced subset of machine learning, relies on network-based architectures to capture complex, non-linear interactions within data. Frameworks like recurrent neural networks (RNNs) and convolutional neural networks (CNNs) have shown potential in forecasting time-dependent drug release behaviour and analysing particle characteristics from image data, respectively [18]. These deep learning approaches often deliver superior performance compared to classical machine learning, especially when applied to large and diverse datasets.

Table 2: Common AI Models and Their Applications in Formulation [4,5,6,16,18]

AI Model	Application in Formulation	Key Advantage
Support Vector Machines (SVM)	Excipient selection, Compatibility prediction	High accuracy in classification tasks
Random Forest	Stability & disintegration time modeling	Handles missing data well
Artificial Neural Networks	Drug release prediction, Dissolution profile optimisation	Captures complex nonlinear patterns
Clustering (Unsupervised)	Grouping similar excipients or formulations	Helps in early-stage screening

CNN / RNN	Particle image analysis / Time-series drug release modelling	Excellent for spatial/temporal data

2.7. NLP (Natural Language Processing)

Natural Language Processing (NLP) is leveraged to extract structured information from unstructured sources such as scientific articles, clinical trial data, and patent documents. By utilising NLP, formulation researchers can efficiently uncover patterns, understand excipient behaviour, and review prior experimental outcomes without needing to manually sift through massive amounts of textual content [19].

2.8. Bayesian and Hybrid Models

Bayesian networks are particularly valuable in managing uncertainty during formulation development, as they allow for probabilistic reasoning. These systems can be integrated with advanced learning algorithms to form hybrid models that merge domain expertise with data-driven learning approaches, enhancing both flexibility and predictive strength [20].

2.9. Software Platforms and Programming Tools

A wide range of artificial intelligence tools and libraries are available to support pharmaceutical formulation. General-purpose platforms such as TensorFlow, Keras, Scikit-learn, and PyTorch offer robust frameworks for developing and training models. Additionally, specialised software like MATLAB, KNIME, and Design Expert cater specifically to formulation scientists, offering intuitive interfaces for tasks like experimental design, data handling, model building, and performance analysis [21,22]. These tools simplify the process from data input to result visualisation, making advanced analytics more accessible to researchers.

Table 3: AI Tools and Software for Formulation Development [21,22]

Tool/Platform	Purpose	Features
TensorFlow	Model development & deep learning	Python-based, GPU acceleration
KNIME	No-code AI tool for pharmaceutical workflows	Drag-and-drop UI, data wrangling
MATLAB	Simulation and predictive modeling	Strong statistical functions
Design-Expert	QbD-based optimization	Statistical DoE, response surface modelling
PyTorch	Custom AI model building	Research-grade flexibility

2.10. Benefits and Drawbacks

Artificial intelligence tools play a transformative role in pharmaceutical development by minimising manual experiments, enabling rapid screening of formulations, and deepening insight into complex processes. Nonetheless, certain challenges persist - such as difficulties in interpreting models, reliance on extensive datasets, and limited adaptability across various drug types [23]. For these technologies to be applied successfully, it is essential to maintain reliable datasets and carry out thorough validation of predictive models.

3. AI'S DIFFICULTIES AND LIMITATIONS IN PHARMACEUTICAL FORMULATION

Although artificial intelligence (AI) has demonstrated significant promise in pharmaceutical formulation, several important obstacles still hinder its broad and effective application across academic and industrial settings.

3.1. Data Integrity and Availability

AI algorithms require access to large, reliable datasets to deliver accurate predictions. Unfortunately, pharmaceutical data is often scattered, inconsistent, or held under proprietary restrictions. Limitations such as incomplete records, small-scale studies, and inconsistencies in lab methodologies can greatly affect the reliability and repeatability of AI outcomes [24].

3.2. Transparency of AI Models

A major limitation - especially with complex models like deep learning - is their opaque decision-making process. These so-called “black box” systems often lack clear explanations for their outputs, making it difficult for researchers or regulators to assess how the algorithm concluded - an essential requirement in the drug development field [25].

3.3. Navigating Regulatory Hurdles

Introducing AI tools into formulation science presents regulatory challenges. Current policies do not offer explicit standards for validating and documenting predictive models, delaying their acceptance in both clinical and manufacturing environments [26].

3.4. Model Adaptability and Consistency

AI tools that are developed using specific data may not perform equally well when applied to new drug compositions, different active ingredients, or varied patient groups. This raises concerns about poor adaptability and limited real-world effectiveness. Moreover, the problem of overfitting - where the model performs well on training data but poorly on unseen data - can further weaken its reliability [27].

3.5. Limited Expertise and Technical Resources

Successfully deploying AI in formulation requires close cooperation between formulation scientists and data analysts. However, many pharmaceutical teams lack the specialised skills or infrastructure needed to implement, monitor, or maintain AI-driven platforms [28].

3.6. Ethical and Privacy Considerations

When AI tools handle patient-specific or real-world clinical data, concerns around ethical data use, patient consent, and information security arise. With laws like GDPR enforcing strict data protection rules, failing to meet these requirements could diminish public trust in digital health systems [29].

Table 4: Key Challenges in Applying AI to Formulation

Challenge	Description
Data Quality	Inconsistent, small datasets hinder prediction accuracy.
Model Interpretability	Difficulty in explaining 'black-box' decisions in regulatory settings
Regulatory Gaps	Lack of formal guidelines for AI-based formulation tools
Transferability	Limited ability to apply one model across APIs or dosage forms
Skill Gaps	Absence of personnel with data science and pharmaceutical integration training [24,25,26,27,28]

4. REGULATORY CONSIDERATIONS

The integration of Artificial Intelligence (AI) into pharmaceutical formulation and drug product development has introduced significant opportunities for improving formulation optimisation, quality prediction, manufacturing efficiency, and personalised medicine.[30] However, because AI-based systems directly influence product quality and patient safety, regulatory compliance has become an essential requirement.[31] Regulatory authorities worldwide are actively developing frameworks to ensure that AI systems used in pharmaceutical development are scientifically validated, transparent, reliable, and compliant with Good Manufacturing Practices (GMP).[32] The implementation of AI should follow a risk-based approach throughout the product lifecycle while maintaining data integrity, patient safety, and regulatory accountability.[33]

Figure 4: Regulatory Framework for AI in Pharmaceutical Formulation



4.1. Compliance with ICH Guidelines

The International Council for Harmonisation (ICH) provides globally accepted guidelines that support AI implementation in pharmaceutical development.

- **ICH Q8(R2) - Pharmaceutical Development** encourages the application of Quality by Design (QbD). AI assists in identifying Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs), allowing formulation scientists to establish an optimised design space with fewer experimental trials.[30]
- **ICH Q9(R1) - Quality Risk Management** recommends systematic risk assessment throughout product development. AI-based predictive models can identify high-risk formulation variables, prioritise experiments, and improve risk mitigation strategies.[31]
- **ICH Q10 - Pharmaceutical Quality System** supports continuous improvement throughout the product lifecycle. AI contributes through predictive quality monitoring, process optimisation, deviation detection, and real-time decision-making.[34]
- **ICH Q12 - Product Lifecycle Management** facilitates post-approval changes using scientific evidence. AI-generated data can support process optimisation and lifecycle management while maintaining product quality and regulatory compliance.[35]

4.2. AI Integration with Quality by Design (QbD)

Quality by Design is now considered the cornerstone of modern pharmaceutical development. AI significantly enhances QbD by analysing large datasets, identifying complex relationships among formulation variables, and predicting optimal formulation conditions.[36]

AI can assist in:

- Identification of Critical Quality Attributes (CQAs)
- Prediction of Critical Material Attributes (CMAs)
- Optimisation of Critical Process Parameters (CPPs)
- Design Space Development
- Process Analytical Technology (PAT)
- Real-Time Release Testing (RTRT)

The integration of AI within QbD minimises trial-and-error experimentation, improves formulation robustness, reduces development costs, and enhances regulatory confidence. [30,36]

4.3. Data Integrity and ALCOA+ Principles

The accuracy of AI predictions depends heavily on the quality of training data. Regulatory agencies require pharmaceutical data to comply with ALCOA+ principles, which ensure:

- Attributable
- Legible
- Contemporaneous
- Original
- Accurate
- Complete
- Consistent
- Enduring
- Available

Poor-quality datasets may introduce bias into AI models, reducing prediction accuracy and increasing regulatory concerns. Therefore, robust data governance and documentation are essential before AI implementation. [36,37,38]

Table 5: Major Regulatory Guidelines for AI in Pharmaceutical Formulation

Guideline	Organization	Purpose	AI Application
ICH Q8(R2)	ICH	Pharmaceutical Development	AI-assisted formulation optimization
ICH Q9(R1)	ICH	Quality Risk Management	AI-based risk assessment
ICH Q10	ICH	Pharmaceutical Quality System	Continuous quality improvement
ICH Q12	ICH	Lifecycle Management	Post-approval lifecycle management
21 CFR Part 11	FDA	Electronic Records	Electronic records & signatures
GAMP 5	ISPE	Computerised System	AI software validation

		Validation	

4.4. Computer System Validation (CSV) and GAMP 5

Since AI models operate as computerised systems, they must comply with GAMP 5 (Good Automated Manufacturing Practice) principles. [37,38,39]

Validation includes:

- Software verification
- Algorithm qualification
- Model validation
- Performance testing
- Cybersecurity assessment
- Change management
- Periodic revalidation

Computer System Validation ensures that AI systems consistently perform according to their intended use throughout their operational lifecycle. [38,39]

4.5. Electronic Records and 21 CFR Part 11 Compliance

When AI systems generate electronic records or support manufacturing decisions, they must comply with US FDA 21 CFR Part 11.[39]

Requirements include:

- Secure electronic records
- Electronic signatures
- Audit trails
- User authentication
- Controlled access
- Data backup
- Record traceability

These requirements ensure regulatory acceptance of AI-generated data during inspections and product submissions. [38,39,40]

4.6. Explainable Artificial Intelligence (XAI)

One of the major regulatory concerns is the "black-box" nature of many deep learning algorithms.

Regulatory agencies prefer Explainable AI (XAI) because it provides:

- Transparent decision-making
- Model interpretability
- Scientific justification of predictions
- Easier regulatory review
- Improved trust among researchers and regulators

Explainability becomes especially important when AI predictions influence formulation selection, manufacturing parameters, or quality decisions. [38,41,42,43,44]

Table 6: Regulatory Challenges and Recommended Solutions for AI - Based pharmaceutical formulation

Challenge	Regulatory Concern	Recommended Solution
Poor Data Quality	Low prediction accuracy	ALCOA+ compliance
Black-box AI	Lack of transparency	Explainable AI (XAI)
Cybersecurity	Data breach	Secure infrastructure
Model Drift	Reduced reliability	Continuous monitoring
Regulatory Acceptance	Lack of harmonisation	Risk-based validation

4.7. Role of Global Regulatory Authorities

Several regulatory agencies are actively developing AI guidance.

- **US FDA** supports AI-based pharmaceutical innovation through a risk-based regulatory approach.[38]
- **European Medicines Agency (EMA)** has published reflection papers addressing AI throughout the medicinal product lifecycle.[39]
- **MHRA (United Kingdom)** is developing AI governance for pharmaceutical applications.[40]
- **WHO** has also emphasised responsible AI implementation in healthcare.[41]

Although comprehensive AI regulations are still evolving, these agencies encourage innovation while maintaining patient safety and product quality.[42]

4.8. Continuous Monitoring and Lifecycle Management

Unlike conventional software, AI models continuously evolve with new data.

Therefore, regulatory expectations include:

- Continuous model monitoring
- Drift detection
- Performance evaluation
- Periodic revalidation
- Version control
- Documentation updates
- Change control procedures

Lifecycle monitoring ensures that AI systems remain accurate, reliable, and compliant throughout commercial manufacturing. [35,37,39,41,43]

4.9. Ethical, Privacy, and Cybersecurity Considerations

AI systems handling patient-specific or manufacturing data must comply with ethical and privacy regulations.

Important regulatory concerns include:

- Patient confidentiality
- Informed consent
- GDPR compliance
- Data security
- Cybersecurity risk assessment
- Prevention of algorithmic bias
- Responsible AI governance

Strong cybersecurity measures protect pharmaceutical manufacturing systems from unauthorised access and data manipulation. [32,44,45,46,47]

4.10. Future Regulatory Perspective

As AI adoption increases, future regulatory frameworks are expected to include:

- Standardised AI model validation guidelines
- Global harmonisation of AI regulations
- Explainable AI requirements
- AI-specific GMP guidance
- Digital twin validation standards
- Real-time AI auditing systems

International collaboration among FDA, EMA, ICH, WHO, and other regulatory agencies

These developments will facilitate wider acceptance of AI in pharmaceutical formulation while ensuring patient safety and product quality. [39,41,42,43,48,49]

Figure 5: AI Model Regulatory Lifecycle: Validation, compliance and continuous monitoring



5. FUTURE PROSPECTS

The application of intelligent systems in pharmaceutical development is expected to evolve rapidly, especially when integrated with emerging technologies. One major area of advancement lies in the adoption of connected frameworks such as the Internet of Medical Things (IoMT), which can enable live process tracking, dynamic response mechanisms, and real-time quality control. This connectivity could significantly enhance product consistency and reduce the likelihood of manufacturing errors [50].

A particularly transformative innovation is the use of "digital replicas" or virtual simulation environments that replicate the behaviour of real-world formulation systems. These tools allow scientists to experiment virtually, predict outcomes, and fine-tune formulation parameters before physical trials - saving both time and resources [51, 52].

Looking ahead, the ability to tailor therapies based on an individual's biological profile will become increasingly viable. Data-driven customisation - incorporating insights from genetics, metabolism, and disease progression - could lead to drug regimens designed to meet the specific needs of each patient. This approach may offer remarkable benefits in areas like pediatric care, cancer treatment, and chronic disease management [53].

To support these advances, there will be a growing emphasis on making AI models more transparent and interpretable. Developing explainable algorithms, along with stronger data handling protocols and

clearer regulatory standards, will be key steps in shifting AI from experimental applications to mainstream use in pharmaceutical science and manufacturing.

6. CONCLUSION

The integration of artificial intelligence into pharmaceutical formulation is no longer a distant innovation it is actively shaping current research and development practices. By assisting in the prediction of excipient behaviour, refining drug release strategies, and minimising unnecessary trial-and-error, AI is transforming the efficiency of formulation science.

Beyond speeding up processes, AI introduces new avenues for creating therapies that are tailored, secure, and centred on patient outcomes. While there are still hurdles - such as ensuring model transparency, maintaining high-quality datasets, and addressing evolving regulatory expectations - these represent stages of progress rather than setbacks.

Importantly, the goal is not to replace scientists but to enhance their capabilities. AI serves as a valuable ally, offering smarter decision-making tools that can improve how medicines are designed, tested, and delivered. Looking ahead, its influence will extend beyond just accelerating drug development - it will redefine the very approach to personalised and equitable healthcare.

REFERENCES:

1. He Y., Ma H., Liu Z., Wang J., “Artificial Intelligence in Drug Formulation: Recent Developments and Future Perspectives”, International Journal of Pharmaceutics, 2020, 588, 119733. https://doi.org/10.1016/j.ijpharm.2020.119733
2. Rajput A., Thakur A., Sharma N., Sharma V., Singh S., “Application of Artificial Intelligence in Pharmaceutical Product Formulation: A Comprehensive Review”, Current Pharmaceutical Design, 2021, 27(15), 1847–1856. https://doi.org/10.2174/1381612826666201112143113
3. Mak K.K., Pichika M.R., “Artificial Intelligence in Drug Development: Present Status and Future Prospects”, Drug Discovery Today, 2019, 24(3), 773–780. https://doi.org/10.1016/j.drudis.2018.11.014
4. Agatonovic-Kustrin S., Beresford R., “Basic Concepts of Artificial Neural Network (ANN) Modelling and Its Application in Pharmaceutical Research”, Journal of Pharmaceutical and Biomedical Analysis, 2000, 22(5), 717–727. https://doi.org/10.1016/S0731-7085(99)00272-1
5. Sharma T., Goyal A.K., Rath G., “Artificial Intelligence: New Avenue for Designing and Developing Drugs”, Asian Journal of Pharmaceutical Sciences, 2020, 15(3), 211–220. https://doi.org/10.1016/j.ajps.2019.10.004
6. Goyal B., Soni N., “Machine Learning Approaches for Drug Formulation: A Review”, Journal of Molecular Structure, 2021, 1227, 129526. https://doi.org/10.1016/j.molstruc.2020.129526
7. Parappil N.S., Kaur N., Jindal P., “Machine Learning Techniques in Pharmaceutical Sciences: An Overview”, Current Pharmaceutical Design, 2022, 28(8), 702–712. https://doi.org/10.2174/1381612826666210803114826
8. Wu H.X., Zhang Y., Yang J.Y., “Role of Machine Learning in Optimization of Oral Drug Formulations”, AAPS PharmSciTech, 2021, 22, 77. https://doi.org/10.1208/s12249-021-01912-3

9. Yu L.X., Amidon G., Khan M.A., Hoag S.W., Polli J., Raju G.K., Woodcock J., "Understanding Pharmaceutical Quality by Design", AAPS Journal, 2014, 16(4), 771–783. https://doi.org/10.1208/s12248-014-9598-3
10. Dey A., Ashour H.M., "Challenges and Future Directions in Artificial Intelligence Applications in Pharmaceutical Sciences", Expert Opinion on Drug Discovery, 2021, 16(6), 601–610. https://doi.org/10.1080/17460441.2021.1885021
11. Ghosh S., Sinha S., Saha S., "Machine Learning in Pharmaceutical Excipient Selection: A Review", Journal of Pharmaceutical Innovation, 2022, 17, 1261–1270. https://doi.org/10.1007/s12247-021-09540-7
12. Dube M., Bhandari A., "Predictive Models for Drug–Excipient Compatibility Using Support Vector Machines", International Journal of Pharmaceutical Sciences and Research, 2021, 12(2), 842–849. https://doi.org/10.13040/IJPSR.0975-8232.12(2).842-49
13. Kalhapure R.S., Akamanchi K.G., "Quality by Design in Pharmaceutical Product Development: A Comprehensive Review", International Journal of Pharmaceutical Investigation, 2020, 10(2), 69–79. https://doi.org/10.4103/jphi.JPHI_29_20
14. Siew A., Leung K.H., Tang P., Wong I.C.K., "Application of AI and Machine Learning in Dosage Form Design: Current Status and Future Perspectives", European Journal of Pharmaceutical Sciences, 2021, 158, 105658. https://doi.org/10.1016/j.ejps.2021.105658
15. Pesapane F., Codari M., Sardanelli F., "Artificial Intelligence in Medical Imaging: Threat or Opportunity? Radiologists Again at the Forefront of Innovation in Medicine", European Radiology Experimental, 2018, 2(1), 35. https://doi.org/10.1186/s41747-018-0061-6
16. International Council for Harmonisation (ICH), "ICH Q2(R2): Validation of Analytical Procedures", Geneva: ICH, 2023.
17. International Council for Harmonisation (ICH), "ICH Q14: Analytical Procedure Development", Geneva: ICH, 2023.
18. European Medicines Agency, "Guideline on Computerised Systems and Electronic Data in Clinical Trials", EMA, 2023.
19. National Institute of Standards and Technology (NIST), "Artificial Intelligence Risk Management Framework (AI RMF 1.0)", Gaithersburg (MD): NIST, 2023.
20. International Organization for Standardization (ISO/IEC), "ISO/IEC 42001:2023 – Artificial Intelligence Management System (AIMS): Requirements", Geneva: ISO, 2023.
21. International Organization for Standardization (ISO/IEC), "ISO/IEC 23894:2023 – Artificial Intelligence: Risk Management", Geneva: ISO, 2023.
22. European Commission, "Artificial Intelligence Act", Brussels: European Union, 2024.
23. Organisation for Economic Co-operation and Development (OECD), "OECD Framework for the Classification of Artificial Intelligence Systems", Paris: OECD Publishing, 2024.
24. Xu X., Yang Y., Li J., Wang J., Liu Y., Chen H., Zhang Z., Sun Q., Zhao X., Huang T., et al., "Data-Driven Pharmaceutical Formulation Design: Progress and Challenges", International Journal of Pharmaceutics, 2021, 598, 120409. https://doi.org/10.1016/j.ijpharm.2021.120409
25. Topol E.J., "High-Performance Medicine: The Convergence of Human and Artificial Intelligence", Nature Medicine, 2019, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

26. Yu K.H., Beam A.L., Kohane I.S., "Artificial Intelligence in Healthcare", Nature Biomedical Engineering, 2018, 2(10), 719–731. https://doi.org/10.1038/s41551-018-0305-z
27. Jiang F., Jiang Y., Zhi H., Dong Y., Li H., Ma S., Wang Y., Dong Q., Shen H., Wang Y., et al., "Artificial Intelligence in Healthcare: Past, Present and Future", Stroke and Vascular Neurology, 2017, 2(4), 230–243. https://doi.org/10.1136/svn-2017-000101
28. Deo R.C., "Machine Learning in Medicine", Circulation, 2015, 132(20), 1920–1930. https://doi.org/10.1161/CIRCULATIONAHA.115.001593
29. Vayena E., Blasimme A., Cohen I.G., "Machine Learning in Medicine: Addressing Ethical Challenges", PLoS Medicine, 2018, 15(11), e1002689. https://doi.org/10.1371/journal.pmed.1002689
30. International Council for Harmonisation (ICH), "ICH Q8(R2): Pharmaceutical Development", Geneva: ICH, 2009.
31. International Council for Harmonisation (ICH), "ICH Q9(R1): Quality Risk Management", Geneva: ICH, 2023.
32. European Medicines Agency, "Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle", Amsterdam: EMA, 2024.
33. World Health Organization, "Ethics and Governance of Artificial Intelligence for Health", Geneva: WHO, 2021.
34. International Council for Harmonisation (ICH), "ICH Q10: Pharmaceutical Quality System", Geneva: ICH, 2008.
35. International Council for Harmonisation (ICH), "ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management", Geneva: ICH, 2019.
36. U.S. Food and Drug Administration, "21 CFR Part 11: Electronic Records; Electronic Signatures", Silver Spring (MD): FDA, 1997.
37. International Society for Pharmaceutical Engineering (ISPE), "GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems", 2nd Edition, North Bethesda (MD): ISPE, 2022.
38. U.S. Food and Drug Administration, "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry", FDA, 2025.
39. U.S. Food and Drug Administration, "Artificial Intelligence and Machine Learning (AI/ML) in Drug Development", FDA, 2025.
40. U.S. Food and Drug Administration, European Medicines Agency, "Guiding Principles of Good AI Practice in Drug Development", FDA–EMA, 2026.
41. Formulation and in vitro study of Ibuprofen loaded crosslinked sodium alginate and gellan gum microspheres. Int J Adv Pharm, 6(3), pp.86-90.
42. World Health Organization, "Regulatory Considerations on Artificial Intelligence for Health", Geneva: WHO, 2023.
43. U.S. Food and Drug Administration, "FDA Proposes Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions", FDA, 2025.
44. Esteva A., Robicquet A., Ramsundar B., et al., "A Guide to Deep Learning in Healthcare", Nature Medicine, 2019, 25(1), 24–29. https://doi.org/10.1038/s41591-018-0316-z

45. Liu X., Faes L., Kale A.U., et al., "A Comparison of Deep Learning Performance Against Health-Care Professionals in Disease Detection from Medical Imaging: A Systematic Review and Meta-analysis", The Lancet Digital Health, 2019, 1(6), e271–e297. https://doi.org/10.1016/S2589-7500(19)30123-2
46. Das, S., Samanta, A., Mondal, S., Roy, D. and Nayak, A.K., 2021. Design and release kinetics of liposomes containing abiraterone acetate for treatment of prostate cancer. Sensors International, 2, p.100077.
47. Kelly C.J., Karthikesalingam A., Suleyman M., Corrado G., King D., "Key Challenges for Delivering Clinical Impact with Artificial Intelligence", BMC Medicine, 2019, 17, 195. https://doi.org/10.1186/s12916-019-1426-2
48. U.S. Food and Drug Administration, European Medicines Agency, "Good AI Practice (GAIP) Principles for Drug Development", FDA–EMA, 2026.
49. European Medicines Agency, "AI Observatory Report 2025: Artificial Intelligence in Medicines Regulation", EMA, 2025.
50. Mouchere H., Cosnier J., Bouza C., Sanchez-Perez A., Marcoux C., Deram P., Harle P., Morel G., Dussouillez P., Urdaci M.C., et al., "Industry 4.0 and Artificial Intelligence: How AI is Reshaping Pharmaceutical Manufacturing", Journal of Pharmaceutical Innovation, 2022, 17, 1592–1605. https://doi.org/10.1007/s12247-021-09571-0
51. Venkatasubramanian V., "The Promise of Artificial Intelligence in Chemical Engineering: Is It Here, Finally?", AIChE Journal, 2019, 65(2), 466–478. https://doi.org/10.1002/aic.16489
52. Aanchal T., Ankita M., Gowri S.C., Arockia M., Snigdha R.B., "Role of Artificial Intelligence and Machine Learning for Enabling IoT-Enabled Healthcare Systems", Research and Applications Towards Mathematics and Computer Science, 2023, 2, 46–58. https://doi.org/10.9734/bpi/ratmcs/v2/5880C
53. Topol E.J., "A Decade of Digital Medicine Innovation", The Lancet, 2019, 394(10206), 482–483. https://doi.org/10.1016/S0140-6736(19)31173-4